Key terms

About ANVS

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ANVS news

May 01 5:32pm ET Annovis Bio CFO Henry Hagopian Resigns, CEO Steps In by TipRanks Apr 30 12:45pm ET Annovis Bio downgraded to Hold from Buy at Maxim by TipRanks Apr 30 7:34am ET Annovis Bio price target lowered to $26 from $36 at Canaccord by TipRanks Apr 30 6:33am ET Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA) by TipRanks Apr 29 12:01pm ET Annovis Bio falls -69.5% by TipRanks Apr 29 10:37am ET Annovis Bio falls after reporting data from Alzheimer study of buntanetap by TipRanks Apr 29 10:28am ET Annovis Bio Inc trading resumes by TipRanks Apr 29 10:01am ET Annovis Bio falls -12.2% by TipRanks Apr 29 9:48am ET Annovis Bio Inc trading halted, news pending by TipRanks Apr 26 8:45am ET Largest borrow rate increases among liquid names by TipRanks Apr 23 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 22 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 18 3:26pm ET Annovis Bio Inc call volume above normal and directionally bullish by TipRanks Apr 16 12:00pm ET Annovis Bio falls -9.6% by TipRanks Apr 15 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 12 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 04 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 03 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 02 8:46am ET Largest borrow rate increases among liquid names by TipRanks Apr 02 6:25am ET Buy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer’s and Parkinson’s Treatments by TipRanks Apr 01 8:16am ET Annovis Bio announces publication on buntanetap by TipRanks Mar 25 8:46am ET Largest borrow rate increases among liquid names by TipRanks Mar 22 10:00am ET Annovis Bio falls -9.0% by TipRanks Mar 21 3:10pm ET Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI) by TipRanks Mar 21 7:40am ET Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS) by TipRanks Mar 21 6:31am ET Analysts Are Bullish on Top Healthcare Stocks: Femasys (FEMY), BioNTech SE (BNTX) by TipRanks Mar 20 4:52pm ET Annovis Bio Promises Market-Impacting Information Release by TipRanks Mar 20 12:00pm ET Annovis Bio rises 30.0% by TipRanks Mar 20 9:47am ET Annovis Bio rises 8.7% by TipRanks Mar 20 7:33am ET Annovis Bio completes data cleaning for Phase II/III study of buntanetap by TipRanks Mar 18 10:00am ET Annovis Bio rises 9.1% by TipRanks
May 04 4:30am ET Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update by NewsFile Apr 28 12:30pm ET Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging by NewsFile Apr 11 4:30am ET Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease by NewsFile Mar 23 4:30am ET Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest by NewsFile Mar 18 4:30am ET Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022) by NewsFile Mar 08 3:30am ET Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022 by NewsFile Mar 03 3:30am ET Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference by NewsFile Jan 25 4:00am ET Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease by NewsFile Jan 10 3:30am ET Annovis Bio Enhances Leadership Team with Two Senior Appointments by NewsFile Jan 05 3:30am ET Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401 by NewsFile Jan 03 3:30am ET Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences by NewsFile

ANVS Financials

1-year income & revenue

Key terms

ANVS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ANVS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Warren Buffett (L), CEO of Berkshire Hathaway, and Vice Chairman Charlie Munger attend the 2019 annual shareholders meeting in Omaha, Nebraska, May 3, 2019.
Johannes Eisele/AFP/Getty Images
Warren Buffett holds first Berkshire Hathaway meeting without Charlie Munger
People walk by the New York Stock Exchange (NYSE) on March 20, 2024 in New York City. The Dow was up slightly in late morning trading as traders analyze the Federal Reserve's latest decision on interest rates.
Spencer Platt/Getty Images
Stocks close higher after softer-than-expected jobs report fuels hopes of an earlier rate cut
People work at a Starbucks in Manhattan on February 02, 2024 in New York City.
Spencer Platt/Getty Images
Restaurants are competing for frugal diners’ dollars
Traders work on the floor of the New York Stock Exchange during afternoon trading on April 09, 2024 in New York City.
Michael M. Santiago/Getty Images/File
Sell in May and go away? Think again